Concepedia

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Bradley J. Monk, James Kauderer, Katherine Moxley, Albert J. Bonebrake, Summer Dewdney, Angeles Alvarez Secord, Frederick R. Ueland, Carolyn M. Johnston, Carol Aghajanian

Gynecologic Oncology · 2018 · 119 citations · 12 references

DOI

Concepts

References

12

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

, , +10

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

, , +17

Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

Steven O’Day, Alexander M.M. Eggermont, Vanna Chiarion‐Sileni et al. · Journal of Clinical Oncology · 2013 · 386 citations · Full text

, , +17

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Maurie Markman, John A. Blessing, Stephen C. Rubin et al. · Gynecologic Oncology · 2005 · 244 citations

, , +13